Visit the Website for Patients 
Français
Subscribe to our newsletter!
Follow the latest news from CATALIS and Clinical Trials Quebec
Approval Performances
DFI17808
Myotonic Dystrophy Phase I/II
- 16.8 weeks
- 1st site activated in Canada
EFC18244 (THESEUS)
Chronic Obstructive Pulmonary Disease (COPD) Phase IIb/III
- 8.6 weeks
EFC18244 (THESEUS)
Chronic Obstructive Pulmonary Disease (COPD) Phase IIb/III
- 10.4 weeks
EFC18418 (CEREN-1)
Chronic Rhinosinusitis with Nasal Polyps Phase III
- 9.8 weeks
- 1st site activated in Canada
EFC18418 (CEREN-1)
Chronic Rhinosinusitis with Nasal Polyps Phase III
- 10.4 weeks
- 2nd site activated in Canada
GenePHIT
Heart Failure Phase II
- 11.6 weeks
- 1st site activated in Canada
GenePHIT
Heart Failure Phase II
- 13 weeks
- Canadian FPI
GenePHIT
Heart Failure Phase II
- 7 weeks
GenePHIT
Heart Failure Phase II
- 9.4 weeks
GenePHIT
Heart Failure Phase II
- 12.6 weeks
GenePHIT
Heart Failure Phase II
- 18.4 weeks
IM045-1018/BALANCE-MSS-1
Neurology Phase II
- 14.8 weeks
INNOVATE
HIV Phase IIb
- 9.8 weeks
KRAScendo 1 (BO45217)
Non-Small Cell Lung Cancer (NSCLC) Phase III
- 9.6 weeks
- 2nd site activated in Canada
MARITIME-CV-20220196
ASCVD and Obesity Phase III
- 3.8 weeks
MARITIME-CV-20220196
ASCVD and Obesity Phase III
- 8 weeks
MARITIME-CV-20220196
ASCVD and Obesity Phase III
- 8.4 weeks
MARITIME-CV-20220196
ASCVD and Obesity Phase III
- 11.8 weeks
MARITIME-CV-20220196
ASCVD and Obesity Phase III
- 15 weeks
MARITIME-HF-20230227
Obesity and Heart Failure Phase III
- 12 weeks
NETTER-3 (CAAA601A62301)
Oncology: GEP-NET Phase III
- 8 weeks
- 2nd site activated worldwide
panSOHO
HER2 Solid Tumors Phase II
- 10.8 weeks
- 1st site activated in Canada
PDY18663
Graves' disease Phase II
- 7.2 weeks